Biotech Stock News

FDA decisions, clinical trial results, and biotech catalyst coverage. Analysis for investors tracking binary events and pipeline risk.

By Basis Report editorial deskReviewed by Basis Report methodology teamMethodology

ORKABriefJun 2 · Jun 2, 2026

Oruka Therapeutics Expands IL-23 Drug Rights But Delays Key IBD Trial

Oruka Therapeutics widened its IL-23 indication rights but delayed IBD dosing timelines, removing a near-term catalyst while Piper Sandler held its Overweight rating.

MANEBriefMay 28 · May 28, 2026

Veradermics Hair-Loss Pill Posts Positive Results in 500-Man Trial

Veradermics' experimental oral hair-loss pill returned positive results in a 500-man trial, marking a key clinical milestone that could accelerate the path toward FDA submission.

APLSAnalysisMay 23 · May 23, 2026

Biogen Closes $5.6B Apellis Acquisition, APLS Delisted

Biogen completed its $5.6 billion acquisition of Apellis Pharmaceuticals on May 14, 2026, paying $41.00 per share in cash plus a contingent value right of up to $4.00, ending APLS's run as an independent public company. The deal closes on a company with $1.11 billion in trailing revenue growing at 60.9% year-over-year, though still reporting quarterly GAAP losses.

IBRXAnalysisMay 18 · May 18, 2026

ImmunityBio Lands BCG Deal as Anktiva FDA Ruling Nears

ImmunityBio is acquiring U.S. rights to the Tokyo strain of BCG to target a decade-long bladder cancer shortage, while a pivotal FDA decision on its Anktiva immunotherapy looms in the same week. Against 167.6% revenue growth and negative $194 million in trailing free cash flow, the company is stacking catalysts as it burns toward commercial scale.

IBRXBriefMay 17 · May 17, 2026

ImmunityBio Grabs BCG Rights Ahead of Make-or-Break FDA Ruling

ImmunityBio is acquiring U.S. rights to Tokyo strain BCG while bracing for an imminent Anktiva FDA ruling, a dual catalyst that creates a binary risk event for shareholders.

OGNBriefMay 1 · May 1, 2026

Organon Gets 24% Sun Pharma Buyout Bid at $13.25 Floor Price

Sun Pharma's all-cash offer for Organon at a 24% premium converts the stock from a fundamentals story into a merger arbitrage trade.

UECBriefApr 29 · Apr 29, 2026

Uranium Energy Corp Pops 9.7% on Burke Hollow Approval, First New U.S. ISR Project in Years

Uranium Energy Corp shares rose 9.7% after Burke Hollow became the first new U.S. ISR uranium project to launch in years, with Vanguard disclosing a 5.15% stake.

ERASAnalysisApr 28 · Apr 28, 2026

Erasca Plunges 40% on Trial Death, Patent Threat

Erasca shares collapsed roughly 40% in after-hours trading after Phase 1 data for ERAS-0015 revealed a treatment-related patient death alongside otherwise strong tumor response rates, while Revolution Medicines added pressure with patent infringement allegations. The stock faces a rare confluence of clinical, legal, and credibility risk that will define its next chapter.

ORKABriefApr 28 · Apr 28, 2026

Oruka Therapeutics Stock Hits Record High on Psoriasis Drug Data, Then Launches $500M Offering

Oruka Therapeutics surged to a record high after Phase IIa data showed 64% skin clearance for its once-yearly psoriasis drug, then launched a $500M public offering that could dilute shareholders.

OGNBriefApr 28 · Apr 28, 2026

Sun Pharma Buys Organon & Co. for $11.75 Billion in All-Cash Deal

Sun Pharma agreed to acquire Organon & Co. for approximately $11.75 billion in an all-cash deal at a 24% premium, sending OGN shares to a 52-week high.

HIMSBriefApr 26 · Apr 26, 2026

Hims & Hers Health Gets JPMorgan's Blessing at $35 — But the FDA Holds the Real Vote

JPMorgan initiated Hims & Hers Health at Overweight with a $35 price target, while Eli Lilly expanded its LillyDirect GLP-1 partnership, but FDA compounding enforcement remains the binary risk to the thesis.

OGNBriefApr 24 · Apr 24, 2026

Sun Pharma's $13 Billion Bid Sends Organon & Co. Surging 31%

Organon shares surged 31% on reports of a $13 billion takeover bid from Sun Pharma, though the deal remains unconfirmed and speculative.

RCUSBriefApr 22 · Apr 22, 2026

Arcus Biosciences Stock Rebounds 7.8% After Lung Cancer Trial Fails — Here's the Twist

Arcus Biosciences discontinued its Phase 3 lung cancer trial for futility, but the stock rebounded 7.8% as analysts flagged Merck's belzutifan failure opening a competitive window in renal cell carcinoma.

NKTRBriefApr 21 · Apr 21, 2026

Nektar Therapeutics Raises $250 Million After Alopecia Drug Sends Stock Up 18%

Nektar Therapeutics is raising $250 million in a public stock offering timed to an 18.3% rally on positive alopecia trial data, a classic biotech move that funds the pipeline but dilutes existing shareholders.

LEGNBriefApr 21 · Apr 21, 2026

Legend Biotech Surges 18% After Eli Lilly Strikes $7 Billion Cancer Therapy Deal

Eli Lilly struck a ~$7 billion deal tied to Legend Biotech's CARVYKTI cancer therapy, sending LEGN shares up as much as 18% for the stock's best session in three years.

KLRABriefApr 18 · Apr 18, 2026

Kailera Therapeutics Raises $625 Million in Biotech's Biggest IPO, Then Pops 63%

Kailera Therapeutics priced one of biotech's largest-ever IPOs at $625 million and saw shares surge roughly 63% on their first day, reflecting intense investor appetite for obesity therapeutics.

TNGXBriefApr 15 · Apr 15, 2026

Tango Therapeutics Overhauls C-Suite With Three Senior Hires to Push Pancreatic Cancer Drug Toward Approval

Tango Therapeutics appointed Matthew Gall as CFO and hired two additional senior executives to accelerate late-stage development of pancreatic cancer drug vopimetostat, a move backed by a concurrent Leerink price target raise.

TVTXBriefApr 15 · Apr 15, 2026

Travere Therapeutics Surges 33% After FDA Approves the Only Drug for Rare Kidney Disease

Travere Therapeutics stock surged after FILSPARI became the first and only FDA-approved treatment for focal segmental glomerulosclerosis, a rare kidney scarring disease with no competing therapies.

SYREBriefApr 14 · Apr 14, 2026

Spyre Therapeutics Hits 4-Year High on Trial Win, Then Sells $300 Million in Stock

Spyre Therapeutics' SPY001 met all Phase 2 endpoints for ulcerative colitis, prompting analyst upgrades and a 4-year share price high, but the company moved quickly to sell $300 million in new stock.

TLXBriefApr 11 · Apr 11, 2026

Telix Pharmaceuticals Jumps After FDA Accepts Brain Cancer Drug Filing

FDA accepted Telix Pharmaceuticals' NDA filing for its brain cancer imaging agent Pixclara, setting up a binary approval catalyst for the $804mn-revenue radiopharmaceutical company.

OGNBriefApr 11 · Apr 11, 2026

Sun Pharma Reportedly Near $12 Billion Deal for Organon, Stock Jumps 25%

Sun Pharmaceutical is reportedly nearing a $12 billion cash acquisition of Organon & Co., sending shares up 25%, though the stock's muted reaction at $8.83 signals deep skepticism about deal completion.

IBRXBriefApr 10 · Apr 10, 2026

ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month

ImmunityBio confirmed its pivotal BCG-naive bladder cancer trial has adequate statistical power for a 2026 supplemental filing, but an FDA warning letter over misleading Anktiva promotional claims has triggered a 21% stock drop and class action lawsuits.

RLAYBriefApr 8 · Apr 8, 2026

Relay Therapeutics Jumps 16% on New Clinical Data for Its Lead Drug Outside Cancer

Relay Therapeutics surged 16% ahead of its first clinical data presentation for Zovegalisib in vascular anomalies, a new therapeutic area that could expand the drug's market beyond oncology.

IBRXAnalysisApr 3 · Apr 3, 2026

ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month

The FDA issued an enforcement action calling ImmunityBio's promotional claims for ANKTIVA "misleading," directly undermining the commercial adoption narrative behind the stock's $6.7 billion valuation. With 31% annual share dilution and $309 million in cash burn against just $113 million in revenue, existing shareholders face value erosion even if the drug succeeds.

RLAYBriefApr 3 · Apr 3, 2026

Relay Therapeutics Jumps 16% on New Clinical Data for Its Cancer Drug in Rare Disease

Relay Therapeutics gained 16% after announcing initial clinical data on Zovegalisib in vascular anomalies at the ISSVA World Congress, potentially validating the drug's platform value beyond oncology.

KODBriefApr 2 · Apr 2, 2026

Kodiak Sciences Aces Second Phase 3 Trial for Zenkuda in Diabetic Retinopathy

Kodiak Sciences reported positive GLOW2 Phase 3 results showing Zenkuda achieved a 62.5% response rate vs 3.3% for sham in diabetic retinopathy, giving the company two pivotal wins and a clear runway to file for FDA approval.

IBRXBriefApr 2 · Apr 2, 2026

ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month

ImmunityBio confirmed statistical power in its pivotal ANKTIVA bladder cancer trial but faces an offsetting FDA warning that turns the stock into a pure regulatory coin flip.

PRAXBriefApr 1 · Apr 1, 2026

Praxis Precision Medicines Wins FDA Priority Review for Relutrigine NDA

Praxis Precision Medicines received FDA acceptance and Priority Review designation for its relutrigine NDA in rare pediatric epilepsy, compressing the approval timeline to roughly 6 months and marking a major de-risking event for the clinical-stage biotech.

KODAnalysisMar 27 · Mar 27, 2026

Kodiak Sciences Needs Second Phase 3 Trial Despite "Superiority" Claims

Kodiak Sciences announced positive GLOW2 Phase 3 results for tarcocimab tedromer, but the need for a second confirmatory study suggests regulatory complexity. Multiple Phase 3 trials typically indicate FDA feedback requiring additional evidence or suboptimal initial results.

WVEBriefMar 26 · Mar 26, 2026

Wave Life Sciences Plunges 56% Despite Obesity Drug Data

Wave Life Sciences stock plummeted 56% after reporting interim Phase 1 data for obesity drug WVE-007 that showed visceral fat reduction but failed to meet investor expectations.

CORTBriefMar 26 · Mar 26, 2026

Corcept Therapeutics Gets FDA Approval for Ovarian Cancer Drug

FDA approved Corcept Therapeutics' Lifyorli combination therapy for platinum-resistant ovarian cancer, marking the company's expansion into oncology.

SRPTAnalysisMar 26 · Mar 26, 2026

Sarepta Surges 35% But Gene Therapy Safety History Signals Major Risk

Sarepta's 35% surge on early siRNA efficacy data creates dangerous asymmetric risk as gene therapy safety issues historically emerge years after initial success. The market celebration ignores regulatory disputes and commercial failure patterns that define this sector.

SRPTBriefMar 26 · Mar 26, 2026

Sarepta Therapeutics Surges 35% on Positive siRNA Trial Data

Sarepta Therapeutics surged 35% after releasing positive early clinical data from siRNA trials targeting neuromuscular diseases FSHD1 and DM1, coupled with a Morgan Stanley price target increase.

CORTAnalysisMar 25 · Mar 25, 2026

Corcept Insider Drops $3.3M Just Before FDA Win Signals Hidden Value

A Corcept insider purchased $3.3 million in shares just before the company's FDA approval for Lifyorli, suggesting management confidence in broader platform value beyond the single approved indication. The timing and magnitude indicate the market is undervaluing Corcept's glucocorticoid receptor antagonist platform potential.

AAPGAnalysisMar 24 · Mar 24, 2026

Ascentage Pharma's Protein Degrader Pivot Signals Traditional Pipeline Crisis

Ascentage Pharma received China IND clearance for BTK protein degrader APG-3288, marking a strategic shift into unproven PROTAC technology. The pivot suggests management lacks confidence in their traditional small molecule programs that likely underpin current valuations.

APGEBriefMar 24 · Mar 24, 2026

Apogee Therapeutics Posts 52-Week Trial Data, Launches $300mn Offering

Apogee Therapeutics reported positive 52-week Phase 2 trial data for Zumilokibart in atopic dermatitis and launched a $300mn public offering to fund accelerated development.